Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.08 USD
Change Today -0.22 / -9.57%
Volume 2.8M
ATRS On Other Exchanges
As of 1:39 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/14 - $3.20
52 Week Low
09/30/14 - $1.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle. Its transdermal gel products comprise Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company also offers OTREXUP, an injection for subcutaneous use indicated for adults with severe active RA, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis, as well as Vibex auto injectors. In addition, it is developing Vibex QS T for testosterone replacement therapy for men who have testosterone deficiency; Vibex QS M with an undisclosed drug for treatment of a CNS indication; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Meda Pharmaceuticals, Inc.; Pfizer Inc; Population Council; and LEO Pharma, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

93 Employees
Last Reported Date: 03/12/15
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $292.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $43.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $391.1K
Head of Human Resources, Senior Vice Presiden...
Total Annual Compensation: $205.2K
Compensation as of Fiscal Year 2014.

antares pharma inc (ATRS) Key Developments

Antares Pharma Seeks Acquisitions

Antares Pharma Inc. (NasdaqCM:ATRS) plans to use the proceeds from the public offering of shares for general corporate purposes, including business development, in-licensing and acquisitions.

Antares Pharma Inc. Regains U.S. Marketing Rights to OTREXUP for Psoriasis Indication Through Termination of LEO Pharma A/S Promotion and Marketing Agreement

Antares Pharma Inc. announced that it has regained U.S. marketing rights to OTREXUP (methotrexate) injection for subcutaneous use for the psoriasis indication through the termination of an exclusive promotion and marketing agreement with LEO Pharma A/S (LEO) for detailing OTREXUP to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults. According to Symphony Health Solutions, dermatology prescriptions written for OTREXUP in the first quarter of 2015 were below 5% of total OTREXUP prescriptions written. The collaboration will end on June 23, 2015. Antares has previously received a total of $10 million in cash from LEO for the right to commercialize OTREXUP to dermatologists. This cash was recorded as deferred revenue and it was being amortized in to licensing revenue over a three-year period. As a result of the termination of the agreement with LEO, Antares expects to recognize the unamortized balance of the deferred revenues related to the agreement ($5.2 million) in the second quarter of 2015.

Antares Pharma, Inc. Announces Settlement of All Litigation Between Antares Pharma, Inc. and Medac Pharma, Inc. and medac GmbH

Antares Pharma Inc. announced that it has settled all litigation between Antares and Medac Pharma Inc. and its parent, medac GmbH. Pursuant to the settlement agreement, the parties will dismiss proceedings related to their respective patents pending before the United States District Court for the District of Delaware, the United States District Court for the District of New Jersey, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, and the Technical Board of Appeal of the European Patent Office. The settlement agreement also provides for a royalty-free cross-license under the patents-in-suit and their families allowing the manufacture and sale of OTREXUP and RASUVO in and for the U.S.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.08 USD -0.22

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biolase Inc $2.04 USD 0.00
Cerus Corp $4.57 USD +0.08
Pluristem Therapeutics Inc $2.75 USD +0.05
STAAR Surgical Co $8.75 USD -0.23
SurModics Inc $24.37 USD -0.54
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at